This HTML5 document contains 139 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n31http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/national-drug-code-directory/
n28http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/chebi/
n13http://www.rxlist.com/cgi/generic/
n15http://linked.opendata.cz/resource/drugbank/patent/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/property/
n12http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/pdb/
n30http://linked.opendata.cz/resource/drugbank/drug/DB01165/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01165
rdf:type
n5:Drug
n5:description
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]
n5:dosage
n6:271B4CFE-363D-11E5-9242-09173F13E4C5 n6:271B4CFF-363D-11E5-9242-09173F13E4C5 n6:271B4D00-363D-11E5-9242-09173F13E4C5 n6:271B4CF6-363D-11E5-9242-09173F13E4C5 n6:271B4CF7-363D-11E5-9242-09173F13E4C5 n6:271B4CF8-363D-11E5-9242-09173F13E4C5 n6:271B4CF9-363D-11E5-9242-09173F13E4C5 n6:271B4CFA-363D-11E5-9242-09173F13E4C5 n6:271B4CFB-363D-11E5-9242-09173F13E4C5 n6:271B4CFC-363D-11E5-9242-09173F13E4C5 n6:271B4CFD-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
9 hours
n5:indication
For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
owl:sameAs
n19:DB01165 n28:DB01165
dcterms:title
Ofloxacin
adms:identifier
n4:XED n14:Ofloxacin n22:C07321 n23:D00453 n24:DB01165 n25:7731 n26:4422 n27:46507574 n29:PA450684 n30:4583 n31:0062-1542-01
n5:mechanismOfAction
Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.
n5:packager
n7:271B4CC8-363D-11E5-9242-09173F13E4C5 n7:271B4CC5-363D-11E5-9242-09173F13E4C5 n7:271B4CC6-363D-11E5-9242-09173F13E4C5 n7:271B4CBF-363D-11E5-9242-09173F13E4C5 n7:271B4CC0-363D-11E5-9242-09173F13E4C5 n7:271B4CD3-363D-11E5-9242-09173F13E4C5 n7:271B4CD4-363D-11E5-9242-09173F13E4C5 n7:271B4CD1-363D-11E5-9242-09173F13E4C5 n7:271B4CD2-363D-11E5-9242-09173F13E4C5 n7:271B4CD7-363D-11E5-9242-09173F13E4C5 n7:271B4CD8-363D-11E5-9242-09173F13E4C5 n7:271B4CD5-363D-11E5-9242-09173F13E4C5 n7:271B4CD6-363D-11E5-9242-09173F13E4C5 n7:271B4CCB-363D-11E5-9242-09173F13E4C5 n7:271B4CCC-363D-11E5-9242-09173F13E4C5 n7:271B4CC9-363D-11E5-9242-09173F13E4C5 n7:271B4CCA-363D-11E5-9242-09173F13E4C5 n7:271B4CCF-363D-11E5-9242-09173F13E4C5 n7:271B4CD0-363D-11E5-9242-09173F13E4C5 n7:271B4CCD-363D-11E5-9242-09173F13E4C5 n7:271B4CCE-363D-11E5-9242-09173F13E4C5 n7:271B4CD9-363D-11E5-9242-09173F13E4C5 n7:271B4CDA-363D-11E5-9242-09173F13E4C5 n7:271B4CE2-363D-11E5-9242-09173F13E4C5 n7:271B4CE3-363D-11E5-9242-09173F13E4C5 n7:271B4CE0-363D-11E5-9242-09173F13E4C5 n7:271B4CE1-363D-11E5-9242-09173F13E4C5 n7:271B4CDB-363D-11E5-9242-09173F13E4C5 n7:271B4CDE-363D-11E5-9242-09173F13E4C5 n7:271B4CDF-363D-11E5-9242-09173F13E4C5 n7:271B4CDC-363D-11E5-9242-09173F13E4C5 n7:271B4CDD-363D-11E5-9242-09173F13E4C5 n7:271B4CC3-363D-11E5-9242-09173F13E4C5 n7:271B4CC4-363D-11E5-9242-09173F13E4C5 n7:271B4CC1-363D-11E5-9242-09173F13E4C5 n7:271B4CC2-363D-11E5-9242-09173F13E4C5 n7:271B4CC7-363D-11E5-9242-09173F13E4C5
n5:patent
n15:5401741
n5:routeOfElimination
Elimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of ofloxacin.
n5:synonym
Ofloxacine 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid OFLX Ofloxacinum Ofloxacino
n5:toxicity
LD<sub>50</sub>=5450 mg/kg (orally in mice)
n9:hasAHFSCode
n10:08-12-18 n10:52-04-04
n5:foodInteraction
Take without regard to meals. Avoid high doses of caffeine.
n5:proteinBinding
32%
n5:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Ofloxacin.htm
foaf:page
n12:flo1181.shtml n13:oflox.htm n21:ofloxacin-drops.html
n5:IUPAC-Name
n8:271B4D05-363D-11E5-9242-09173F13E4C5
n5:InChI
n8:271B4D0B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n8:271B4D0A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n8:271B4D07-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n8:271B4D08-363D-11E5-9242-09173F13E4C5
n5:SMILES
n8:271B4D09-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n8:271B4D03-363D-11E5-9242-09173F13E4C5 n8:271B4D1B-363D-11E5-9242-09173F13E4C5
n5:logP
n8:271B4D01-363D-11E5-9242-09173F13E4C5 n8:271B4D04-363D-11E5-9242-09173F13E4C5 n8:271B4D1D-363D-11E5-9242-09173F13E4C5
n5:logS
n8:271B4D02-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n16:S01AE01 n16:S02AA16 n16:J01MA01
n5:H-Bond-Acceptor-Count
n8:271B4D11-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n8:271B4D12-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n8:271B4D0C-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n8:271B4D0D-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n8:271B4D0F-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n8:271B4D0E-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n8:271B4D10-363D-11E5-9242-09173F13E4C5
n5:absorption
Bioavailability of ofloxacin in the tablet formulation is approximately 98%
n5:affectedOrganism
Enteric bacteria and other eubacteria
n5:casRegistryNumber
82419-36-1
n5:category
n5:containedIn
n17:271B4CED-363D-11E5-9242-09173F13E4C5 n17:271B4CEE-363D-11E5-9242-09173F13E4C5 n17:271B4CEB-363D-11E5-9242-09173F13E4C5 n17:271B4CEC-363D-11E5-9242-09173F13E4C5 n17:271B4CF1-363D-11E5-9242-09173F13E4C5 n17:271B4CF2-363D-11E5-9242-09173F13E4C5 n17:271B4CEF-363D-11E5-9242-09173F13E4C5 n17:271B4CF0-363D-11E5-9242-09173F13E4C5 n17:271B4CE5-363D-11E5-9242-09173F13E4C5 n17:271B4CE6-363D-11E5-9242-09173F13E4C5 n17:271B4CE4-363D-11E5-9242-09173F13E4C5 n17:271B4CE9-363D-11E5-9242-09173F13E4C5 n17:271B4CEA-363D-11E5-9242-09173F13E4C5 n17:271B4CE7-363D-11E5-9242-09173F13E4C5 n17:271B4CE8-363D-11E5-9242-09173F13E4C5 n17:271B4CF5-363D-11E5-9242-09173F13E4C5 n17:271B4CF3-363D-11E5-9242-09173F13E4C5 n17:271B4CF4-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n8:271B4D17-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n8:271B4D19-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n8:271B4D1A-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n8:271B4D1C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n8:271B4D16-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n8:271B4D15-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n8:271B4D18-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n8:271B4D06-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n8:271B4D13-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n8:271B4D14-363D-11E5-9242-09173F13E4C5